FDA Extends Review Of Application For Full Approval Of Regeneron’s COVID-19 Antibody Therapy

Reuters (4/14, Khandekar, Roy) reports, “The U.S. Food and Drug Administration has extended by three months its review of Regeneron Pharmaceuticals Inc’s application for the full approval of its COVID-19 antibody therapy [casirivimab and imdevimab], the U...